Biohaven Ltd. (BHVN) Stock Price & Growth Analysis

Quote Panel

Updated October 3, 2025

1W 7.84 % 1M -1.62 % 3M 14.65 % 1Y -66.81 %

Key Metrics

Market Cap
1.67B
Shares Outstanding
105.79M
Share in Float
88.38M
Dividende
0

Earning Date
11 Nov 2025
Price Target
15.81
Average Volume
2.56M
Beta
3.449

Range
12.79-55.7
Industry
Biotechnology
Website
https://www.biohaven.com
Sector
Healthcare

Quote Panel

Updated October 3, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

N/A

P/E Ratio

432.15x

P/S Ratio

11.92x

P/B Ratio

2.1

Debt/Equity

-19994.0%

Net Margin

$-7.5

EPS

How BHVN compares to sector?

P/E Ratio

Fundamentals

Relative Strength

BHVN

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

BHVN

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$108M

3873%

2026-Revenue

$5.98

22%

2026-EPS

$77M

3873%

2026-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

0.00(N/A)

Number of analyst

Last analyst upgrade/downgrade

Citigroup

initialise

Previous: Not converted

2025-09-17

Now: Buy

Raymond James

initialise

Previous: Not converted

2025-09-02

Now: Strong Buy

Jefferies

initialise

Previous: Not converted

2024-09-16

Now: Buy

Bernstein

initialise

Previous: Not converted

2024-09-04

Now: Outperform

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q3.23

N/A

-1.50
vs -1.75

Q4.23

N/A

-1.81
vs -3.32

Q1.24

N/A

-2.20
vs -1.03

Q2.24

N/A

-3.64
vs -1.32

Q3.24

N/A

-1.70
vs -1.50

Q4.24

N/A

-1.85
vs -1.81

Q1.25

N/A

-2.17
vs -2.20

Q2.25

N/A

-1.94
vs -3.64

Q3.25

N/A

-1.88
vs -1.70

Q4.25

N/A

-1.80
vs -1.85

Sales Growth

YoY

Current

Estimates

Q3.23

NA vs NA

Q4.23

+100%

NA vs -215079000

Q1.24

NA vs NA

Q2.24

NA vs NA

Q3.24

NA vs NA

Q4.24

3.8M vs NA

Q1.25

NA vs NA

Q2.25

NA vs NA

Q3.25

375.1K vs NA

Q4.25

-40%

2.3M vs 3.8M

Return on Equity

QoQ

Q1.23

-15%

-0.15
vs -0.37

Q2.23

-23%

-0.23
vs -0.15

Q3.23

-35%

-0.35
vs -0.23

Q4.23

-34%

-0.34
vs -0.35

Q1.24

-60%

-0.60
vs -0.34

Q2.24

-83%

-0.83
vs -0.60

Q3.24

-51%

-0.51
vs -0.83

Q4.24

-44%

-0.44
vs -0.51

Q1.25

-85%

-0.85
vs -0.44

Q2.25

-147%

-1.47
vs -0.85

Institutionnal Ownership

QoQ

Q1.23

192

192
vs 192

Q2.23

206

206
vs 192

Q3.23

198

198
vs 206

-4%

Q4.23

232

232
vs 198

17%

Q1.24

267

267
vs 232

15%

Q2.24

237

237
vs 267

-11%

Q3.24

266

266
vs 237

12%

Q4.24

269

269
vs 266

Q1.25

279

279
vs 269

Q2.25

260

260
vs 279

-7%

Earnings Growth

YoY

Current

Estimates

Q3.23

N/A

-1.50
vs -1.75

Q4.23

N/A

-1.81
vs -3.32

Q1.24

N/A

-2.20
vs -1.03

Q2.24

N/A

-3.64
vs -1.32

Q3.24

N/A

-1.70
vs -1.50

Q4.24

N/A

-1.85
vs -1.81

Q1.25

N/A

-2.17
vs -2.20

Q2.25

N/A

-1.94
vs -3.64

Q3.25

N/A

-1.88
vs -1.70

Q4.25

N/A

-1.80
vs -1.85

Sales Growth

YoY

Current

Estimates

Q3.23

NA vs NA

Q4.23

+100%

NA vs -215079000

Q1.24

NA vs NA

Q2.24

NA vs NA

Q3.24

NA vs NA

Q4.24

3.8M vs NA

Q1.25

NA vs NA

Q2.25

NA vs NA

Q3.25

375.1K vs NA

Q4.25

-40%

2.3M vs 3.8M

Return on Equity

QoQ

Q1.23

-15%

-0.15
vs -0.37

Q2.23

-23%

-0.23
vs -0.15

Q3.23

-35%

-0.35
vs -0.23

Q4.23

-34%

-0.34
vs -0.35

Q1.24

-60%

-0.60
vs -0.34

Q2.24

-83%

-0.83
vs -0.60

Q3.24

-51%

-0.51
vs -0.83

Q4.24

-44%

-0.44
vs -0.51

Q1.25

-85%

-0.85
vs -0.44

Q2.25

-147%

-1.47
vs -0.85

Institutionnal Ownership

QoQ

Q1.23

192

192
vs 192

Q2.23

206

206
vs 192

Q3.23

198

198
vs 206

-4%

Q4.23

232

232
vs 198

17%

Q1.24

267

267
vs 232

15%

Q2.24

237

237
vs 267

-11%

Q3.24

266

266
vs 237

12%

Q4.24

269

269
vs 266

Q1.25

279

279
vs 269

Q2.25

260

260
vs 279

-7%

Earnings Growth

Forecast

$108M

3873%

2026-Revenue

$5.98

22%

2026-EPS

$77M

3873%

2026-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

0.00(N/A)

Number of analyst

Last analyst upgrade/downgrade

Citigroup

initialise

Previous: Not converted

2025-09-17

Now: Buy

Raymond James

initialise

Previous: Not converted

2025-09-02

Now: Strong Buy

Jefferies

initialise

Previous: Not converted

2024-09-16

Now: Buy

Bernstein

initialise

Previous: Not converted

2024-09-04

Now: Outperform

Company Description

15.81USD

N/A

432.15x

11.92x

2.1

-19994.0%

$-7.5

$108M

$5.98

$77M

Earnings Growth

Latest News

Latest News

Latest News

Earnings Growth

$108M

$5.98

$77M

Company Description

15.81USD

N/A

432.15x

11.92x

2.1

-19994.0%

$-7.5